The Daily Toke

April 25, 2026

Federal rescheduling of medical marijuana moved from Schedule I to Schedule III on April 23, when Acting Attorney General Todd Blanche signed the order directing the Drug Enforcement Administration to reclassify state-licensed medical cannabis products. The shift, following President Trump's December executive order directing the change, marks what cannabis advocates are calling the most significant federal cannabis-policy move in generations—though the reality on the ground will unfold far more gradually than the headline suggests. The DOJ order applies specifically to state-authorized medical marijuana and FDA-approved cannabis products, leaving recreational marijuana firmly in Schedule I territory while a broader hearing on non-medical cannabis is scheduled for June 29 in Virginia.

💰 MONEY MOVES The immediate financial beneficiaries are medical marijuana dispensaries and operators in the 40 states with existing medical programs. By moving cannabis to Schedule III—the same category as ketamine and anabolic steroids—the federal government removes Section 280E of the Internal Revenue Code, which had barred dispensaries from deducting ordinary business expenses like payroll and rent from their tax liability. Operators in Texas, Arizona, Colorado, and other states with active medical programs are now eligible for federal tax benefits that could substantially reduce their tax burden, possibly as soon as this year. This also opens the door for legitimate banking relationships and research opportunities that were previously off-limits under Schedule I classification. Universities and research institutions in states like Texas can now pursue cannabis studies without the federal legal jeopardy they faced before.

The rescheduling triggered unexpected legal consequences in some states with dormant cannabis statutes. South Carolina, which has long resisted marijuana legalization and attempted to ban THC-infused products like drinks and gummies, discovered it has a nearly 50-year-old law—the Controlled Substances Therapeutic Research Act of 1980—that automatically requires the state to mirror federal scheduling changes. The statute mandates South Carolina's Department of Public Health to "obtain marijuana through whatever means he deems most appropriate consistent with federal law" for a controlled therapeutic research program serving cancer, radiology, and glaucoma patients. Governor Henry McMaster's office confirmed the state has no choice in the matter: state law §44-53-160(c) requires automatic mirroring of federal rescheduling decisions. The legislature may ultimately need to act to clarify what this looks like in practice, but for now, South Carolina finds itself legally bound to follow the federal move despite decades of resistance.

What the rescheduling explicitly does not do is federally legalize marijuana, restore normal banking services to dispensaries, or grant workplace or firearm protections to registered patients—issues that cannabis advocates say remain unresolved and will require separate federal action. Recreational marijuana remains Schedule I under federal law and illegal in most states, though 24 states have legalized recreational use alongside their medical programs. Idaho and Kansas continue to ban medical marijuana entirely within their borders, and the new federal classification doesn't override state sovereignty to maintain prohibition. The order does acknowledge that cannabis "does not produce serious outcomes" like Schedule I or II drugs and has lower potential for abuse than its previous classification suggested, essentially reversing decades of federal narrative about the substance.

🤔 THINK ABOUT IT The rescheduling also leaves unresolved the question of past convictions: thousands of Americans remain incarcerated or have criminal records for marijuana offenses that the federal government now acknowledges warranted Schedule III status, not Schedule I. For advocates pushing criminal justice reform alongside drug policy normalization, the rescheduling is progress but falls short of the comprehensive reset many sought. The broader recreational marijuana hearing beginning in June will determine whether the Trump administration moves on Trump's stated intention to reschedule all marijuana, though both Colorado and Arizona observers note that cannabis-related progress has historically moved slowly despite promising federal signals. Meanwhile, Senator Amy Klobuchar and Senator Rand Paul—an unusual bipartisan pairing—are co-sponsoring legislation that would let states opt out of a federal hemp-THC ban, signaling that cannabis normalization is becoming a genuinely cross-partisan issue, even as implementation details remain contested across statehouses and federal agencies.

April 25, 2026

Missouri Governor Mike Kehoe signed legislation Thursday that will remove all intoxicating hemp products from store shelves starting November 12, aligning state law with a federal ban that Congress approved in November with bipartisan support—151 ayes and 28 nays across both chambers. The move will eliminate THC seltzers currently sold in bars and grocery stores, as well as other hemp-derived products containing up to 1,000 mg of THC that have been operating in an unregulated gray market through smoke shops and convenience stores. The governor framed the action as child safety: "Missouri needs to be a place where it's safe to be able to have your children get access to a product that doesn't include harmful intoxicants," Kehoe said before signing. The bill includes a safety valve—if Congress reverses the ban and permits these products, Missouri would only allow sales through licensed marijuana dispensaries.

💰 MONEY MOVES The hemp industry in Missouri is facing existential pressure. The Missouri Hemp Trade Association called the bill's passage a dismantling of "an industry built by real Missourians who have operated in good faith under existing federal and state law," and the association gathered 10,000 handwritten letters from small-business owners, farmers, and customers in just 10 days asking the governor to veto. Despite that grassroots effort, Kehoe signed anyway, and Missouri Attorney General Catherine Hanaway is already using state consumer-protection laws to crack down on hemp retailers—a enforcement campaign that will accelerate once the November deadline hits.

Meanwhile, the federal picture is far messier. White House officials are simultaneously signaling openness to hemp regulation frameworks. On Tuesday, staffers from the Domestic Policy Council and legislative affairs office sent Rep. Andy Barr (R-KY)—a key figure pushing for legal hemp markets—draft legislative language aimed at protecting CBD access while restricting what the administration calls products posing "serious health risks." Barr had filed a hemp amendment to the Farm Bill that would preserve legal THC product sales under a regulatory framework banning synthetics and ensuring American-origin products, but he later withdrew it without explanation. Meanwhile, Rep. Mary Miller (R-IL) filed a competing amendment that would accelerate the hemp ban to whenever the new Farm Bill passes, rather than waiting until November.

🤔 THINK ABOUT IT This landscape creates a genuine puzzle for consumers and veterans especially. Intoxicating hemp products—which contain zero recorded overdose deaths in human history—are being treated as an urgent public health threat requiring immediate elimination. Alcohol, which kills approximately 95,000 Americans annually, remains legal and widely available. Prescription opioids kill over 16,000 Americans per year and remain legal and heavily prescribed. Many veterans rely on THC products for PTSD, chronic pain, and anxiety management; accelerating a ban without robust alternatives raises real questions about access to care for those communities.

The House Appropriations Committee added another dimension this week when it approved language directing federal agencies to study the "adequacy" of state marijuana regulatory frameworks and to assess methods for preventing diversion of legally produced cannabis from legalization states into prohibition states. The committee recognized that over 20 states and territories now permit adult-use cannabis while 35+ permit medicinal use, and asked the Treasury Department's Alcohol and Tobacco Tax and Trade Bureau to coordinate a comprehensive assessment including recommendations on data sharing between state and federal authorities—findings to be reported back within one year. This suggests at least one congressional committee is trying to build regulatory infrastructure rather than pursue blanket prohibition, even as other lawmakers push faster timelines for hemp elimination.

The 2026 cannabis landscape is fracturing: Missouri moves toward total elimination, the Trump administration explores regulatory frameworks, Congress proposes competing timelines, and federal agencies prepare to study what's already working in two dozen states. None of this resolves the fundamental tension between state legal markets and federal scheduling, or between the public rationale for these policies and the documented harms of alternatives left untouched.

April 25, 2026

Federal legislators and state officials are intensifying efforts to crack down on hemp-derived THC products, setting the stage for a potential clash between Congress, state governments, and a $28 billion industry that has exploded in the regulatory gray space created by the 2018 Farm Bill. According to reporting from November 2025, Congress has begun pushing for hemp restrictions after sustained pressure from states and the traditional marijuana industry, with the federal government specifically targeting what officials describe as a "loophole" that has allowed companies to produce and sell intoxicating hemp products containing delta-8, delta-10, and other cannabinoids in states where marijuana remains illegal. 💰 MONEY MOVES CNBC reported that congressional hemp restrictions threaten the entire $28 billion industry, sending companies scrambling to understand what a federal crackdown would mean for their operations, supply chains, and ability to continue selling products in states like Texas where hemp-derived THC has become a de facto alternative to banned cannabis.

The push for federal restrictions reflects a broader tension between federal drug policy and emerging state-level markets. Texas, in particular, has become a flashpoint—USA Today reported in April 2026 that the state is actively pursuing a THC flower crackdown despite the legal ambiguity created by federal hemp legalization. The situation reveals a stark irony: while traditional cannabis remains a Schedule I controlled substance at the federal level, hemp-derived products containing intoxicating levels of THC have proliferated in states where cannabis prohibition remains in place. This regulatory uncertainty has created a booming commercial landscape where producers can legally manufacture and distribute products that would be illegal if derived from cannabis plants rather than hemp—a distinction based on plant genetics rather than biochemical effects.

🤔 THINK ABOUT IT If Congress bans hemp-derived THC products to "protect" consumers and children, it's worth considering what they're actually protecting people into: states where cannabis remains criminalized are seeing residents turn to less-regulated hemp markets, where product testing and quality standards vary wildly, rather than accessing products from regulated legal cannabis markets where testing is mandatory and potency is controlled. The legislative push, while framed as consumer protection, may instead force consumers toward riskier alternatives or the unregulated market entirely—the exact opposite of stated public health goals.

The crackdown also carries direct consequences for veterans and chronic pain patients who have relied on legal hemp-derived THC products for PTSD, anxiety, and pain management in states where medical cannabis access remains limited or prohibited. With zero recorded overdose deaths from cannabis in human history—compared to 95,000 annual deaths from alcohol and 16,000+ from prescription opioids—the federal prioritization of hemp restrictions over those substances raises questions about the actual hierarchy of public health concerns. Missouri Times reporting from November 2025 highlighted that the federal government is specifically looking to close what it calls the hemp THC loophole, suggesting a coordinated effort rather than scattered state action.

South Carolina, according to Greenville Online reporting from November 2025, faces the prospect of both federal restrictions and possible state-level bans that could eliminate the hemp industry entirely in that state. The convergence of federal action and state restrictions suggests a coordinated effort to re-establish prohibition, despite the fact that hemp legalization has created jobs, generated tax revenue, and provided access to products in areas where traditional cannabis markets remain closed. 💰 MONEY MOVES The question facing Congress now is whether the benefits of this emerging legal market—jobs, tax revenue, access for people in prohibition states—outweigh the regulatory challenges that have accompanied it, or whether the political pressure from traditional cannabis interests and concerned states will override those economic considerations. The outcome will determine whether hemp-derived THC products persist as a legal category or whether the 2018 Farm Bill's legalization of hemp becomes a historical footnote to a return to broader prohibition.

April 25, 2026

Scientific evidence on cannabis therapeutics remains deeply mixed, with major reviews finding limited proof of benefit across most medical conditions while isolated studies highlight genuine promise in specific areas—leaving patients, clinicians, and policymakers in a frustrating gap between enthusiasm and proof.

The New York Times and Newswise both reported in December 2025 that comprehensive reviews of medical cannabis use found insufficient evidence to support its effectiveness for most conditions doctors and patients have turned to it for. The findings underscore a persistent problem: while cannabis has entered mainstream medicine cabinets and state-legal dispensaries across North America, rigorous clinical trials proving its benefits remain sparse. 🚀 THIS IS COOL In sharp contrast, a January 2026 scientific review published by Marijuana Moment found that cannabidiol (CBD)—the non-intoxicating compound in cannabis—shows "substantial promise" in combating tumor growth in cancer research, signaling that the plant's therapeutic window may be far narrower and more specific than popular perception suggests.

UCHealth's clinical trial program, detailed in March 2026 reporting, represents exactly the kind of rigorous infrastructure the field desperately needs. These controlled studies aim to separate genuine therapeutic signals from anecdotal hope, a crucial distinction when patients are making decisions about their health. Science Daily's December 2025 investigation into cannabis and chronic pain explored what the plant "really does" beyond folklore—recognizing that millions of people report relief while acknowledging that mechanism and efficacy remain scientifically contested terrain. 🤔 THINK ABOUT IT Alcohol causes approximately 95,000 deaths annually in the United States, prescription opioids kill over 16,000 per year, and cannabis has never caused a single recorded overdose death in human history—yet cannabis remains Schedule I while both legal substances generate tens of billions in corporate revenue and tax income.

The core problem isn't that cannabis lacks therapeutic potential; it's that Schedule I classification, in place since 1970 despite President Nixon's own Shafer Commission recommending decriminalization, has made federal funding for rigorous research nearly impossible for over five decades. 💰 MONEY MOVES States that have legalized cannabis are now investing in the clinical infrastructure—universities, hospitals, trial networks—that the federal government has largely abandoned, creating a patchwork where evidence accumulates at the state and private level rather than through coordinated national research. Britannica's comprehensive overview of the medical marijuana debate acknowledged both the genuine arguments on each side and the urgent need for clarity, a rare note of intellectual honesty in a conversation too often dominated by ideology rather than data.

What emerges from these overlapping reports is a field in transition: cannabis has moved from prohibition's shadow into the light, but the evidence has not yet caught up with either the enthusiasm of advocates or the skepticism of traditionalists. Chronic pain patients, cancer researchers, and clinical teams are operating in a zone of partial information—some benefits documented, many claims unproven, the plant's full therapeutic range still largely unmapped. 💰 MONEY MOVES The race is on for whichever institutions, states, and research programs can establish credible evidence first, because whoever owns the data on which cannabinoids work for which conditions will shape the next decade of medicine. Until then, science continues its deliberate work while patients continue their urgent search for relief.

April 25, 2026

# Texas Cannabis News Briefing

I've reviewed the articles provided, and I need to be direct with you: none of them contain any information about cannabis, hemp, or cannabis policy in Texas or elsewhere. The articles are exclusively about Texas A&M athletics — specifically football recruiting, baseball standings, the 2026 NFL Draft results, and sports forum discussions.

There is no cannabis news here to report on.

If you intended to provide articles about Texas cannabis legislation, industry developments, medical applications, or policy changes, please share those sources and I'll write the briefing immediately. Otherwise, I cannot ethically generate a cannabis news briefing from sports content that contains zero cannabis information — that would be fabrication, not journalism.

What you've sent me reads like it may have been a misfiled batch of links. Do you have the correct Texas cannabis articles you'd like me to cover?